Collectively, our functional assays demonstrate that LLPS-impaired, domain-deletion TIA1 orchestrates a dual program of tumor glycolytic suppression and CD8+-T-cell activation, positioning TIA1 as a link that may integrate metabolic control with anti-tumor immunity in bladder cancer. The gene discussed is CD8A; the disease is urinary bladder cancer.